Dispense Times Magazine

05/07/2026

Most vendors think their problem is traffic.

It’s not. It’s trust.

People don’t:

stop

engage

or buy

from brands they don’t trust yet.

👉 Trust is built before the conversation.

That’s what consistent visibility does.

If your audience doesn’t recognize you, they’re not choosing you.

Ads don’t close. They build trust.

info@dispensemarketing.com

05/01/2026

Pharmacies are closing.

Most people think it is Amazon.
Or inflation.

It is not that simple.

Pharmacies are being paid less than what it costs to buy and dispense medications.

What used to show up later as fees is now built into the price at the point of sale.

Lower reimbursement from the start.
Less room to operate.

Patients are steered into certain networks.
Choice gets smaller.

All of it adds up.

When a pharmacy closes, it is not just a business going away.

A community loses access.
Patients lose convenience.
Care gets harder to reach.

This is not random.

It is how the system is structured.

We are losing local pharmacies.

Communities feel it.
Patients feel it.

Follow for more breakdowns.

04/30/2026

Everyone is talking about PBM reform.

Very few are talking about how to actually turn it into revenue.

That’s the real opportunity.

The pharmacies that win won’t just wait for change—they’ll know how to capture value when it shows up.

In this issue, we break that down and highlight companies like Waypoint who are helping pharmacies navigate that shift.

👉

In this issue: Mel Chancey joins us for a conversation on second chances, preventive care, and the pharmacist’s role in what comes next. We also explore how personalization became pharmacy’s best business model in Made to Order, break down The GLP 1 Showdown from TrumpRx and compounding crackdow...

04/29/2026

We made the world of marketing.

https://worldofdtcmarketing.com/the-war-against-pbms-is-just-getting-started-and-its-about-time/?fbclid=IwRlRTSARfTOZleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEenSBjew4YfpPJEDGLJ2sEZHcacaWQ6LumBCD1YfkGfP2EtGGjc89F7Q7wwng_aem_UAcHPM12KgCKH-W7WAvOeA

Pharmacy Benefit Managers (PBMs) have quietly become some of the most powerful—and least understood—players in the U.S. healthcare system. Companies like CVS Caremark, Express Scripts, and OptumRx control access to medications for over 80% of Americans

04/26/2026

The future of pharmacy isn’t just dispensing.

It’s clinical.

From GLP-1s to expanded services like birth control prescribing, pharmacies are stepping into a much bigger role in patient care.

The question is:
👉 Who’s helping them get there?

In this issue, we spotlight companies like InfoWerks who are supporting pharmacies in that transition.

👉

In this issue: Mel Chancey joins us for a conversation on second chances, preventive care, and the pharmacist’s role in what comes next. We also explore how personalization became pharmacy’s best business model in Made to Order, break down The GLP 1 Showdown from TrumpRx and compounding crackdow...

04/25/2026

For every $1 CVS Health paid in fines, enforcement actions have cited an estimated $12 to $58 in alleged damages.

Let that sink in.

This isn’t speculation.
It’s based on publicly reported settlements, complaints, and audits over the past three decades.

Now here’s the part that matters:

When penalties are a fraction of the alleged harm, they don’t function as deterrents.

They function as economic tradeoffs.

Think about the math in plain terms.

If the downside is limited, the behavior doesn’t disappear.
It gets priced in.

That’s not about one company or one case.
That’s how the system is structured.

And it helps explain what pharmacists are seeing every day:

Margins under pressure
Opaque reimbursement
Consolidation at the top
Pricing that doesn’t make sense at the counter

This isn’t just a pharmacy issue either.

Patients feel it through higher costs and fewer choices.
Employers feel it through rising plan spend.
Taxpayers feel it through public program dollars.

The bigger question isn’t whether enforcement exists.

It’s whether it changes behavior.

Because if the incentives don’t change, the outcomes won’t either.

The system is producing exactly what it incentivizes

04/24/2026

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

April 24 () - Bristol-Myers Squibb and Pfizer said on Friday they will start selling ‌their jointly developed blood thinner through billionaire ‌entrepreneur Mark Cuban's online pharmacy beginning April 27. • Patients with ​a prescription will pay $345 for a 30-day supply of the blockbuster ...

04/24/2026

Pharmacy isn’t evolving… it’s being forced to adapt.

Inside this issue:
• The real impact of GLP-1 disruption
• Why personalization is no longer optional
• How PBM reform could quietly unlock revenue
• What forward-thinking pharmacies are doing differently right now

The gap between pharmacies that adapt and those that don’t is widening.

👉

In this issue: Mel Chancey joins us for a conversation on second chances, preventive care, and the pharmacist’s role in what comes next. We also explore how personalization became pharmacy’s best business model in Made to Order, break down The GLP 1 Showdown from TrumpRx and compounding crackdow...

04/24/2026

FDA Crackdown Ends the Shortage Loophole: What the New GLP-1 Compounding Rules Mean for Pharmacies

The FDA has closed the shortage loophole that fueled the compounded GLP-1 boom. With semaglutide and tirzepatide off the shortage list, compounding pharmacies and telehealth platforms face a new era of enforcement, audits, and market consolidation.

04/23/2026

This article is a big deal if you’re in pharmacy, telehealth, or anything GLP-1 related.

The FDA just made it very clear:
the window for widespread compounding of GLP-1 drugs is closing.

Here’s what it actually means:

GLP-1 drugs like semaglutide and tirzepatide exploded in demand for weight loss and diabetes.
That demand created shortages… and compounding pharmacies stepped in to fill the gap.

Now supply is stabilizing.

And the FDA is saying:
that changes everything.

👉 Compounding is only allowed when there’s a shortage
👉 Once the shortage is resolved, you can’t make “copies” of approved drugs
👉 If you do, you risk enforcement action

And they defined “copy” pretty aggressively:

If it’s the same ingredient, similar dose, and same route…
it’s considered a copy.

Even adding something like B12 doesn’t automatically make it different.

They also made this clear:

Compounded GLP-1 drugs are not FDA approved
They haven’t been reviewed for safety or effectiveness
And mass marketing them like brand drugs is a problem

What this really means:

This is the beginning of a crackdown.

Telehealth companies, compounding pharmacies, and anyone building a business around compounded GLP-1s
are now operating in a much tighter lane.

Short-term:
You’ll see less availability of compounded versions

Long-term:
This shifts power back to manufacturers and FDA-approved products

The bigger takeaway:

Compounding was never meant to replace commercial drugs.
It was meant to fill gaps.

Now that the gap is closing…
so is the opportunity.

If you’re in this space, this isn’t just policy.

It’s a business model shift happening in real time.

https://www.mondaq.com/unitedstates/healthcare/1775412/fda-clarifies-policies-for-pharmacy-compounders-of-glp-1-products

Connect with experienced intellectual property attorneys at Foley & Lardner LLP's Chicago office. Our legal professionals specialize in patent law, trademark protection, and IP litigation, offering strategic counsel to protect your innovations and creative assets.